XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.3
Note 7 - Share-based Compensation (Details Textual)
$ / shares in Units, $ in Millions
9 Months Ended 12 Months Ended
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
$ / shares
shares
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Number Of Active Stock Incentive Plans 1        
Number Of Inactive Stock Incentive Plans 1        
Performance Shares [Member]          
Performance Share Award Target Level, Percentage 100.00%        
Performance Awards Issued Multiplier     133.00% 111.00% 118.00%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number At Target Level Of Performance (in shares) 172,000        
Performance Shares [Member] | Minimum [Member]          
Performance Awards Issued Multiplier 0.00%        
Performance Shares [Member] | Maximum [Member]          
Performance Awards Issued Multiplier 200.00%        
Restricted Stock Units and Performance Stock Awards [Member]          
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ $ 4.9        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 1 year 7 months 6 days        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) [1] 107,065        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares $ 42.41        
Stock Awards [Member] | Director [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 12,996 14,424      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares $ 39.23 $ 33.27      
[1] The number of PSAs disclosed in this table are at the target level of 100%.